Get The Spin Brief
CRISPRMRIimmunotherapyclinical trialorganoidsbiological age
Public companyCompany profile · informational

Vertex Pharmaceuticals

Vertex develops small-molecule and genetic medicines for serious diseases and is best known for its cystic fibrosis drugs. It co-developed Casgevy, the first FDA-approved CRISPR-based therapy, with CRISPR Therapeutics, and has expanded into non-opioid pain treatment.

Verified highlights each with its source

  • FDA approved Casgevy (exagamglogene autotemcel) for sickle cell disease on Dec. 8, 2023 — the first FDA-approved therapy using CRISPR/Cas9 genome editing.
    Source: fda.gov ↗
  • FDA approved Journavx (suzetrigine), an oral non-opioid NaV1.8 pain-signal inhibitor for moderate-to-severe acute pain, on Jan. 30, 2025 (company release).
    Source: news.vrtx.com ↗

Sources

  1. en.wikipedia.orgen.wikipedia.org
  2. fda.govfda.gov
  3. news.vrtx.comnews.vrtx.com

Science and stocks are different questions. This profile describes scientific and regulatory progress. It says nothing about whether the company’s shares will rise or fall, and it is not a recommendation to buy, sell or hold any security.

Disclosure. Spin Pharma has no financial relationship with this company and holds no position in it.

Related

Coverage mentioning this company

Abstract editorial illustration of a DNA double helix unspooling into lines of glowing letters, some highlighted and some faded to suggest known and unknown meaning.Genome + Cells
Mixed / overview

Decode the Genome: What Sequencing Can Tell Us—and What It Cannot

From the $3 billion Human Genome Project to routine sequencing, reading DNA has become easy. Here is what a genome can reveal today, and where uncertain variants, risk scores and missing context set hard limits.

Explainer5 min read